Crow et al. discovered that previously unreported somatic mutations in the Mothers Against Decapentaplegic Homolog 4 (SMAD4) enhanced the chemo-resistance of epithelial ovarian cancer. The gene discussed is SMAD4; the disease is ovarian carcinoma.